SCHEMBL13629320

SCHEMBL13629320

CCc1ccc(NS(=O)(=O)c2ccccc2Cl)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 4/20 0.54
ALDH1A1 P00352 4/20 0.52
PGR P06401 1/20 0.51
HIF1A Q16665 1/20 0.51
LMNA P02545 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GAA P10253 1/20 0.50
BRD4 O60885 2/20 0.49
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629401 0.89 ALDH1A1 (0.65) SLC22A12ALDH1A1PGRLMNAMEN1
SCHEMBL13853039 0.89 SLC22A12 (0.64) SLC22A12ALDH1A1PGRHIF1ALMNA
SCHEMBL13629415 0.87 MEN1 (0.57) SLC22A12ALDH1A1HIF1ALMNAMEN1
SCHEMBL13629329 0.85 ALDH1A1 (0.65) ALDH1A1LMNAMAPT
SCHEMBL13629338 0.85 SLC22A12 (0.53) SLC22A12ALDH1A1PGRHIF1ALMNA
SCHEMBL13629424 0.84 ALDH1A1 (0.62) SLC22A12ALDH1A1PGRLMNAMEN1
SCHEMBL13629339 0.83 BRD4 (0.51) ALDH1A1LMNABRD4MAPT
SCHEMBL20575861 0.82 SLC22A12 (0.56) SLC22A12ALDH1A1PGRLMNAMEN1
SCHEMBL13629773 0.81 ALDH1A1 (0.57) SLC22A12ALDH1A1MEN1KMT2ABRD4
SCHEMBL13615035 0.81 SLC22A12 (0.54) SLC22A12ALDH1A1PGRHIF1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK SLC22A12 4663/4885ALDH1A1 2057/4885PGR 1506/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK SLC22A12 4627/4885ALDH1A1 2121/4885PGR 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.